



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n 4 : A61K 37/02	A1	(11) International Publication Number: WO 88/ 06451 (43) International Publication Date: 7 September 1988 (07.09.88)
(21) International Application Number: PCT/US88/00576 (22) International Filing Date: 23 February 1988 (23.02.88) (31) Priority Application Number: 018,324 (32) Priority Date: 24 February 1987 (24.02.87) (33) Priority Country: US (71) Applicant: XOMA CORPORATION [US/US]; 2910 Seventh Street, Berkeley, CA 94710 (US). (72) Inventors: MISCHAK, Ronald, P. ; 3095 Greer Road, Palo Alto, CA 94303 (US). SCANNON, Patrick, J. ; Route 2, Box 2141, Davis, CA 95616 (US). SPITLER, Lynn, E. ; 71 Reed Ranch Road, Tiburon, CA 94920 (US). HARKONEN, W., Scott ; 3018 Sacramento Street, San Francisco, CA 94115 (US). MILLER, Langdon ; 379 - 15th Avenue, San Francisco, CA 94118 (US).	(74) Agent: SMITH, William, M.; Townsend and Townsend, One Market Plaza, 2000 Steuart Tower, San Francisco, CA 94105 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent). Published With international search report.	
(54) Title: IMMUNOSUPPRESSION IN IMMUNOTOXIN BASED HUMAN THERAPY (57) Abstract Novel methods for immunotoxin based human therapy in which immunosuppressive amounts of cyclophosphamide, azathioprine, cyclosporine or 6-mercaptopurine are co-administered to enhance the long term effectiveness of the immunotoxin and diminish complications from the patient's immune response to the immunotoxin. The cyclophosphamide may be used in combination with other agents in managing the patient's treatment for various diseases, such as cancers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

IMMUNOSUPPRESSION IN IMMUNOTOXIN BASED HUMAN THERAPY5 Field Of The Invention

This invention relates generally to methods for improving the effectiveness of immunotoxins in chemotherapy and other human treatment applications and, more particularly, to the concurrent administration of
10 immunosuppressive agents in extended treatment regimes with immunotoxins.

BACKGROUND OF THE INVENTION

The development of hybridoma technology by
15 Kohler and Milstein in 1975 was heralded as a major technology breakthrough for the fields of immunology and medicine. For the first time, researchers were able to transform B-lymphocytes to create hybrid cells, with immortal potential, capable of secreting monoclonal
20 antibodies, i.e., a single species of antibody reactive with a single type of epitope on a selected antigen. In practice, however, applying monoclonal antibody technology to improve chemotherapeutic and other therapies has been extremely difficult. In the decade since the
25 discovery, very few therapeutic successes have been reported, despite extensive research efforts.

One reason for the lack of successful human therapeutic treatment regimes, at least in tumor therapy, is the fact that the mere binding of a monoclonal anti-
30 body to a target cell frequently does not induce cell death. To overcome this problem, there were considerable efforts devoted to coupling monoclonal antibodies to various cytotoxic agents capable of killing targeted cells. The monoclonal antibody would act as a "magic
35 bullet", delivering the cytotoxic agent specifically to the desired cell. These immunoconjugates are known as "immunotoxins."

While treatment studies with immunotoxins have been widespread and to some extent successful, the use of immunotoxins is often curtailed by a patient's immune response to both the monoclonal antibody and the toxin components of the immunotoxin. It is particularly thought to be a problem when the monoclonal antibody is of mouse or other non-human origin, although a patient's production of anti-idiotypic antibodies could cause significant diminishment of the usefulness of immunotoxins even when made with human monoclonal antibodies.

An immune response against immunotoxin can cause premature removal of the immunotoxin from the patient's serum, significantly limiting the immunotoxin's effectiveness. Multiple treatment regimes are extremely susceptible to this problem, and increasing the immunotoxin dosage is generally undesirable, in part because the patient may suffer allergies and other harmful effects of immune reactions against the immunotoxin.

Thus, there is significant need for new methods of immunotoxin treatment, wherein the host immune response is abrogated or at least diminished to a level such that extended immunotoxin treatments are feasible. These methods of treatment should not include agents that are incompatible with immunotoxins or that will increase the amount of immunotoxin required to be administered to the patient. Ideally, the treatment methods will not substantially increase the toxicity of the overall therapy. The present invention fulfills these needs.

SUMMARY OF THE INVENTION

The present invention provides novel methods for enhancing the effectiveness of immunotoxin based therapy in human patients, which methods comprise concurrent administration of an immunosuppressive dose of cyclophosphamide in conjunction with the immunotoxin. Alternatively, immunosuppressive doses of cyclosporin, 6-mercaptopurine and azathioprine may be co-administered.

These novel treatments have particular applicability in multiple dose treatment regimes using immunotoxin compositions, such as in chemotherapy when utilizing multiple injections of ricin A-chain conjugated to monoclonal antibodies specifically reactive with melanoma or other tumor associated antigens.

The immunosuppressive agent(s) can be administered concomitantly with the monoclonal antibody composition to obtain immunosuppression of at least about 50% to 85%. The dose will vary with each particular application, and typically the agent will be administered orally or as an intravenous injection. The doses will range widely, depending on the agent used and the administration interval, which can range from a single injection to multiple injections over a few days or greater than two weeks. In accordance with the present invention, various administration intervals and dosages which produce a substantially decreased immune response to the immunotoxin compositions are contemplated to permit multiple treatment regimes with the immunotoxin. If desired, cocktails containing additional compositions capable of adequately reducing the undesired immune response may be included.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Novel methods are provided for improving immunotoxin based therapy in human patients by inhibiting the patient's immune response through the co-administration of at least one immunosuppressive dose of cyclophosphamide, cyclosporin, 6-mercaptopurine, or azathioprine with the immunotoxin. These agents, which can be utilized with prednisone, diminish the patient's immune response in a dose responsive manner and prolong the efficacy of the immunotoxin, enhancing the patient's prognosis for recovery. Moreover, in multiple immunotoxin treatment regimes, the total immunotoxin dose may be reduced.

Cyclophosphamide is a synthetic cytotoxic agent originally designed to improve the selectivity of alkylating compounds and is chemically related to the nitrogen mustards. It has a molecular formula of $C_7H_{15}Cl_2O_2P.H_2O$, its molecular weight is 278.1 and its full chemical name is: 2-bis[(2-chloroethyl)amino]-tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate. Cyclophosphamide is available commercially and is sold, for example, under the registered trademarks CYTOXAN, by Bristol Meyers Corporation in Syracuse, New York, or NEOSAR, by Asta-Werke A.G., Bielefeld, Germany.

To be effective, cyclophosphamide is thought to require metabolic activation, and the drug and its metabolites are broadly distributed throughout the body after intravenous administration. Cyclophosphamide has a serum half life of about 4 hours, however, the drug and its metabolites are generally detectable in plasma up to 72 hours.

Cyclophosphamide is soluble in water, saline or ethanol and is suitable for parenteral or oral administration. Cyclophosphamide solutions may be given intravenously, intramuscularly, intraperitoneally, or intrapleurally. If desired, the solutions may be infused intravenously with dextrose and/or sodium chloride. (See, generally, Cancer Principles and Practice of Oncology, eds. DeVita et al, 2nd Ed. J. B. Lippincott Company, Philadelphia (1985), which is incorporated herein by reference.)

Appropriate dosages of cyclophosphamide (indeed, all of the immunosuppressive agents of the present invention) to achieve the desired immunosuppressive effect will vary to some extent depending on the individual patient's condition, on the particular immunotoxin composition administered, and on the patient's past exposure to the immunotoxin or related compositions. The suppression of the immune response is adequate to enable a second course of immunotoxin to be administered

without neutralization or accelerated elimination by the patient's antibodies.

Treatment with cyclophosphamide and the other immunosuppressive agents is potentially hazardous to the patient, so continuous monitoring for harmful side effects should be maintained. In particular, a marked leukopenia is usually associated with significant doses. (See generally, Physicians Desk Reference, 42nd Edition (1988), which is incorporated herein by reference.)

Also, patients receiving certain immunotoxins have shown a reversible decrease in voltage on EKG not associated with either cardiac abnormalities and other constitutional symptoms that generally disappear within two weeks after treatment. Typically, there is no overlap between the toxicity of moderate doses of cyclophosphamide and the immunotoxin.

Another suitable agent, cyclosporine A, is a cyclic polypeptide ($C_{62}H_{111}N_{11}O_{12}$) immunosuppressant comprising 11 amino acids. It is produced as a metabolite by the fungus species Tolypocladium inflatum Gams.

Cyclosporine A is a potent immunosuppressive agent by an unknown mechanism of action, and is widely used in animals to prolong survival of allogeneic organ transplants. When administered in high doses, however, hepatotoxicity and nephrotoxicity can result.

Cyclosporine A is soluble in ethanol and slightly soluble in water. It is typically administered orally or intravenously, and can be purchased under the trademark SANDIMMUNE by Sandog, Ltd, Basle, Switzerland.

Other immunosuppressive agents include 6-mercaptopurine (MP) and its imidazolyl derivative azathioprine. The former is a well known antineoplastic and the latter an antimetabolite more commonly used in immunosuppression. MP is insoluble in water, but soluble in hot ethanol and alkaline solutions. Azathioprine is slightly soluble in water and ethanol. Both are

available commercially, MP under the trademark PURINETHOL and azathiopurine under the trademark IMURAN, from Burroughs Wellcome Corporation, Research Triangle Park, North Carolina, U.S.A.

5 Immunotoxins are characterized by two components. One component is the cytotoxic agent which is fatal to a cell when absorbed. The second component, known as the "delivery vehicle," provides a means for delivering the toxic agent to a particular cell type,
10 such as cells comprising a carcinoma. The two components are commonly chemically bonded together by any of a variety of well-known chemical procedures. For example, when the cytotoxic agent is a protein and the second component is an intact immunoglobulin, such as a mono-
15 clonal antibody, the linkage may be by way of heterobifunctional cross-linkers, e.g., SPDP, carbodiimide, gluteraldehyde, or the like. Production of various immunotoxins is well-known within the art, and can be found, for example, in "Monoclonal Antibody-Toxin Con-
20 jugates: Aiming the Magic Bullet", Thorpe et al, Monoclonal Antibodies in Clinical Medicine, Academic Press, pp 168-190 (1982), which is incorporated herein by reference.

A variety of cytotoxic agents are suitable
25 for use in immunotoxins. Cytotoxic agents can include radionuclides, such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cis-platinum; and cytotoxic proteins such as ribosomal in-
30 hibiting protein, pokeweed antiviral protein, abrin and ricin (or their A-chains, diphtheria toxin A-chains, pseudomonas exotoxin A, etc. (See generally, "Chimeric Toxins", Olsnes and Phil, Pharmac. Ther., 25:355-381 (1982), and "Monoclonal Antibodies for Cancer Detection
35 and Therapy," eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985), both of which are incorporated herein by reference.)

The delivery vehicle component of the immunotoxin can be obtained from a number of sources. Intact immunoglobulins or their fragments, such as Fv, Fab, F(ab₂), etc., may be used. Preferably, the immunoglobulins are monoclonal antibodies of the IgM or IgG isotype, of mouse, human or other mammalian origin.

A preferred source of monoclonal antibodies is immortalized murine or human cell lines that may be cloned and screened in accordance with conventional techniques. However, recent technical advances have provided additional forms of immunoglobulins and methods of making them. For example, the utilization of recombinant DNA technology has produced functional, assembled immunoglobulins or hybrid immunoglobulins (e.g., the constant region from human monoclonal antibodies combined with mouse variable regions), suitable for use in immunotoxins. (See, e.g., EPA 84302368.0, which is incorporated herein by reference.)

Typically, the antibodies are capable of binding to epitopes of markers on selected cell types, such as neoplastic cells. The marker is generally a unique surface protein and a variety of markers, such as other proteins, glycoproteins, lipoproteins, polysaccharides and the like, which are produced by the cells to be treated, can be utilized in accordance with the present invention. The general immunization fusion, screening, and expansion methods of monoclonal antibody technology are well-known to those skilled in the art and do not form part of the present invention.

A preferred method of measuring the immune response to an immunotoxin is based on the common ELISA assay. Briefly, microtiter plates are coated with the immunotoxin components, i.e., the immunoglobulin and the cytotoxic agent. After standard blocking and washing procedures, appropriate dilutions of patient's serum are added to the plate and any antibodies in the serum binding to the antigens are detected using an alkaline

phosphatase conjugated goat anti-human antibody with heavy chain specificity for IgM or IgG. The antibody response is typically reported as a ratio. For each patient, the maximum measurable binding activity following therapy is determined by extrapolating the titration curve to the X axis. The response ratio is defined as a ratio of the titration end point value of the maximum response to the end point value of the patient's pre-treatment (baseline) serum. Other protocols may be substituted to assess the patient's immune response according to means well known by those skilled in the art.

By utilizing each patient's pre-treatment's serum as a baseline reference, positive responses to both the immunoglobulin and the cytotoxic agent components of the immunotoxin can be identified. Typically, the humoral aspect of the immune response is analyzed and a wide range of responses to each and/or both of the immunotoxin components is seen.

Based on control response studies and on data from various additional studies, an abrogation or prevention of the development of an immune response is indicated by a ratio less than about 2.0. An acceptable inhibition of a human immune response to either or both components of an immunotoxin would be preferably less than about 5.0 to 10 for both components, most preferably less than about 2.0 to 3.0.

To achieve a suitable reduction of a human immune response, a variety of dosage protocols may be followed, again, depending, e.g. upon the particular immunotoxin utilized and the condition of the patient. The amount of cyclophosphamide administered per injection may range from about 50 mg/m^2 up to about $1,500 \text{ mg/m}^2$ or more. Larger amounts per injection may be tolerated if the administration schedule calls for a single or a few injections. Lower amounts per

injection may be administered over longer time periods of up to two weeks or more.

In one dose protocol, between 350 and 600 $\text{mg}/\text{m}^2/\text{day}$, more preferably from about 400 to 550 $\text{mg}/\text{m}^2/\text{day}$, and most preferably about 500 $\text{mg}/\text{m}^2/\text{day}$, of cyclophosphamide is administered in five injections over a period of about 18 days. The initial three injections are preferably administered on alternate days on the first five days after treatment with immunotoxin, and the remaining two injections administered at four to six day intervals thereafter.

Alternatively, the cyclophosphamide may be administered in a single intravenous injection of between about 750 and 1,250 mg/m^2 preferably about 1,000 mg/m^2 between 4 and 24 hours or more after the initial immunotoxin injection. Yet another schedule entails administering about 14 daily injections, each of about 100 mg/m^2 . Longer treatments with lower doses are preferred. Similarly, for cyclosporin A, the dose will typically range from about 3 to 15 $\text{mg}/\text{kg}/\text{day}$ from 3 to 60 days. For 6-mercaptopurine, the usual dose will range from 1.5 to 7.5 $\text{mg}/\text{kg}/\text{day}$ from 1 to 24 days. For azathioprene, the dose will range from 1 to 5 $\text{mg}/\text{kg}/\text{day}$ for 3 to 60 days, typically in conjunction with prednisone at a dose range of 0.1 to 1.0 $\text{mg}/\text{kg}/\text{day}$ over the same time period. If desired, the doses may be administered prior to the immunotoxin treatment, typically beginning about one week before such treatment.

An effective immunosuppressive dose would be an amount of immunosuppressive agent sufficient to limit the patient's immune response to a significantly reduced level of interference with the functional activity of the immunotoxin (e.g., to a level where a subsequent immunotoxin dose regimen retains substantial efficacy). This corresponds to the inhibiting the immune response in comparison to a normal response, ideally by about 85% to 95% or more, but inhibition levels of about 50%

to 60% may be acceptable in some patients, and at least about 75% inhibition is preferred. Diminishment of various components of the immune response may be obtained, but reduction in antibody formation is a preferred result.

The period of co-administration of immunotoxin and immunosuppressive agent ideally should be coincided. In humans, the IgG response commonly can be detected about 7 to 8 days after exposure to the immunotoxin, and peaks at about 15 to 20 days or more thereafter. To minimize the IgG response, for example, the immunosuppressive agent is preferably administered primarily within the first few days after initial exposure to the immunotoxin. Subsequent doses may be administered to further abrogate this or other aspects of the immune response.

In this manner, prolonged or multiple treatment therapy regimes with the immunotoxin can be utilized to provide an increased level of therapeutic efficacy. Also, the total immunotoxin dose is minimized. Immunotoxin doses will vary widely according to the treatment.

Various combinations of immunotoxin and immunosuppressive agent administration schemes are acceptable for use with susceptible diseases, such as malignant tumors. The neoplasms suitable for treatment in accordance with the present invention include those neoplasms showing retarded growth or total remission when subjected to immunotoxin treatment. For example, such neoplasms include melanomas, gastrointestinal carcinomas, various leukemias, and T-cell and B-cell lymphomas. Aggressive grades of cancers are particularly suited for treatment with immunotoxins.

Immunotoxins also find use in other human therapies. By way of example, and not limitation, immunotoxins can be used to treat autoimmune diseases, graft rejection and graft versus host disease in allogeneic

bone marrow transplantation, and graft rejection in other organ transplants.

Depending on the disease to be treated, cyclophosphamide, cyclosporine, 6-mercaptopurine and azathioprine may be used alone or with other immunosuppressive agents. These "cocktails" can be designed to universally and safely suppress immune responses in a wide variety of treatment regimes. Any of a variety of additional immunosuppressant agents known to the skilled artisan can be combined in the cocktail. For example, prednisone may be utilized with cyclophosphamide, azathioprine or cyclosporine at concentrations ranging from about 50 to 250 mg/m², preferably about 100 mg/m². Similarly, dexamethasone may be utilized with the cyclophosphamide at doses of about 5 to 30 mg, preferably about 15 mg. Typically, all of the immunosuppressive agents will be given coincidentally, such as both at day one, or both on five daily injections, or the like, but alternating administrations may be utilized. Actual methods for preparing and administering oral and parenteral compositions will be known or apparent to those skilled in the art and are described in detail, e.g., in Remington's Pharmaceutical Science, 16th Ed., Mack Publishing Co., Pennsylvania (1982), which is incorporated herein by reference.

The following examples are offered by way of illustration and not limitation.

EXPERIMENTAL

30

Example I

The immunotoxin utilized is XMMME-001-RTA as disclosed fully in U.S. Patent No. 4,590,071, which is incorporated herein by reference. The delivery portion of the immunotoxin is a monoclonal antibody secreted by a hybridoma designated XMMME-001, which was deposited with the American Type Culture Collection prior to the filing of the present application and designated

Accession No. HB8759. This monoclonal antibody recognizes human melanoma associated antigen expressed on two glycoproteins with molecular weights of about 280 kd and about 440 kd. These antigens are expressed on a large majority of melanomas, a low percentage of squamous and basal cell carcinomas, but generally not in normal tissues of ectodermic, mesodermic, endodermic origin. The surface markers are heterogeneous in expression among lesions isolated from different patients and among sites within the tumor cell population.

The cytotoxic agent of this immunotoxin, labeled "RTA", consists of the ricin toxin A-chain, which has been separated from whole ricin in accordance with the teachings of U.S. Patent No. 4,590,071. The RTA is reduced and linked to the XMMME-001 antibody using succinimidyl 3-(2-pyridyldithio) propionate, which facilitates formation of disulphide bridges between the two components. The modified antibody is conjugated with the reduced ricin A-chain, purified, and then prepared for injection.

The administration of the XMMME-001-RTA is accomplished by slow intravenous infusion, generally completed within 30 minutes to one hour. It is generally not administered as an intravenous push or bolus.

In preliminary patient studies, clinical trials demonstrated that a single course of XMMME-001-RTA alone could be administered to patients safely and showed indications of efficacy in patients with metastatic melanoma. The use of cyclophosphamide alone for treatments of melanoma is unlikely to be effective (less than 13% response in a limited number of patients; see, Mastrangelo, et al in Cancer Principles and Practice of Oncology, eds. DeVita et al, J. P. Lippincott Co., Philadelphia pp 1,156 et. seq. (1985)).

Six patients having a documented history of metastatic malignant melanoma, Stage III disease, received 0.1 mg./kg/day of XMMME-001-RTA for five

consecutive days in conjunction with cyclophosphamide. The first day of immunotoxin infusion is considered to be day one. Cyclophosphamide was administered by IV push over 2 to 10 minutes on days 2, 4 and 6, 12 or 13, and 16 or 17. On days when both cyclophosphamide and the immunotoxin were given, the cyclophosphamide dose was administered about 1 to 4 hours after the immunotoxin dose. There was no noticeable interaction between the immunotoxin and cyclophosphamide in their distribution, metabolism or excretion.

Three different doses of cyclophosphamide were administered. Three patients received 300 mg/m^2 , two patients received 400 mg/m^2 (one of these received the cyclophosphamide for only the first three days), and one patient received 500 mg/m^2 . Serum samples were collected prior to treatment and at weekly intervals for a minimum of four weeks. The samples were analyzed for antibody reactivity to the immunotoxin using a standard ELISA assay. Briefly, the assay entailed absorbing the XMMME-001 or ricin A-chain (RTA) to microtiter plates, which were then treated with glycine or bovine serum globulin for blocking. Appropriate dilutions of serum samples were incubated at 4° overnight and the amount of human immune globulin bound to the absorbed antigen was identified as IgM or IgG using alkaline phosphatase conjugated heavy chain specific goat antihuman IgM or IgG. After an hour incubation with the antibody-enzyme conjugate, the substrate P-nitrophenylphosphate was added and incubated for one hour and optical densities (at 405 nm) were recorded.

The antibody response is reported as a response ratio. For each patient, the maximum measurable binding activity following therapy is determined by extrapolating the titration curve to the X axis. The response ratio is defined as the ratio of the titration end point value of the maximum response to the end point value of the patient's pre-treatment (baseline) serum.

14

By using each patient's pre-treatment serum as his/her baseline reference, we have been able to clearly identify positive responses to both the immunoglobulin and to the Ricin A Chain components of the immunotoxin (Table I). A wide range of response rates are demonstrated. The mean Ig ratio is 13.9 ± 15.9 SD. The mean A chain response ratio is 138.2 ± 208 SD. Thus, the response ratios were dispersed over a wide range and the ratios were generally considerably greater for an immune response to the ricin A-chain in comparison to the XMMME-001.

15

20

25

30

35

TABLE I

RESPONSE TO XMMME-001

RESPONSE TO RICIN A CHAIN

(Endpoint Dilution 1×10^{-3})

Patient	IT Dose (mg/kg/day)	Baseline	Max	M/B	Baseline	Max	M/B
1	0.50	3.2	30	9.4	0.1	10	100
2	0.50	2.0	50	25	0.1	24	240
3	0.50	50	100	2	0.1	5	50
4	0.5	6	200	33	1.2	200	166
5	0.50	3.2	5	1.6	1.6	20	12.5
6	0.50	2.4	10	4.2	1	300	300
7	0.75	2	4	2	1	1	1
8	0.75	1	1	1	1	1	1*
9	0.50	1	40	40	0.2	50	250
10	0.20	1.5	13	8.6	3.2	10-100	3-33
11	0.75	1	1.6	1.6	-	-	-
12	0.50	1.2	10	8.3	0.4	80	200
13	0.20	0.4	1.6	4	0.3	200	666
14	0.75	2	16	8	0.2	160	800
15	1.0	0.4	9	22.5	0.15	2.5	16.7
16	1.0	2-10	100-64	50-6.4	2	10	5
17	0.50	0.4	1	2.5	0.1	6	60
18	0.50	3	100	33	3.2	150	46.8
19	0.20	0.25	0.45	1.8	0.2	9	45
20	0.20	0.4	3	7.5	0.4-0.1	8-7	20-70
21	0.05	2.5-1	125-10	50-10	0.5	40	80
22	0.01	0.7	1	1.4	0.7	8	12

* Samples to Day 3

The surprising results of cyclophosphamide addition inhibiting the IgG immune response are shown in Table II. The three patients receiving doses of 300 mg/m² showed a more regular base line reactivity than
5 the patient in Table I. The mean ratio against the immunoglobulin was about 8.2, and against ricin A-chain the ratio was about 25. In addition, the response ratio to the ricin A-chain clustered in the range of about 20 to 30. In particular, cyclophosphamide substantially
10 reduced the immune response in the patients receiving doses of 400 or 500 mg/m². In patient 5, there was a minimal IgG response to the monoclonal antibody, but this patient did not receive the full cyclophosphamide regime. Otherwise, the patients' response to ricin-A
15 and XMMME-001 was either minimal or not detectable.

20

25

30

35

TABLE II

RESPONSE TO XMME-001 RESPONSE TO RICIN A CHAIN

(Endpoint Dilution 1×10^{-3})

<u>Patient</u>	<u>IT*</u>	<u>Dose</u>	<u>CTX**</u>	<u>Baseline</u>	<u>Max</u>	<u>M/B</u>	<u>Baseline</u>	<u>Max</u>	<u>M/B</u>
A01	0.1	300		0.1	1.2	12	0.05	1.2	24
A02	0.1	300		0.1	0.8	8	0.1	3.2	32
A03	0.2	300		1.5	7	4.7	0.1	2	20
A04	0.1	400		0.05	0.1	2	0.05	0.08	1.6
A05	0.1	400		0.1	0.6	6	0.05	0.15	3
A06	0.1	500		0.05	0.05	1	0.05	0.1	2

17

* mg/kg/day

** mg/m²

Example II

Utilizing the same procedures as in the prior example, the immunosuppressive capability of azathioprine, cyclosporine A and 6-mercaptopurine were analyzed in a
5 separate clinical trial. The results are shown in Table III.

TABLE III

RESPONSE TO XMME-001 RESPONSE TO RICIN A CHAIN

Immunosuppressive Regimen	Patient	Max	M/B	Max	M/B
Control	JC-01	6,000	60	2,400	6
IT dose	BW-05	6,400	64	10,000	100
0.4 mg/kg x 1	HS-30	1,200	12	800	8
	RB-60	1,200	12	1,000	4
	WG-201	6,400	9.1	800	8
	AS-30	1,200	12	800	8
Cyclophosphamide	TD-61	100	1	100	1
100 mg/m ² /d x 14	JR-62	400	2	3,200	2.9
	HZ-63**	100	1	100	1
	Retreat	1,600	16	100	1
	Retreat	2,000	3.3	100	1
	SH-64	20,000	6.3	80,000	800
Cyclophosphamide	JD-09	3,200	32	30,000	75
400 mg/m ² x 5 d	JK-10*	6,400	6	5,000	16.6
+	Retreat	15,000	75	---	---
Prednisone	HR-11	20,000	25	120,000	80
100 mg/d x 5 d					

*Patient retreated

+Positive skin test before next treatment (treatment not given)

TABLE III (Continued)

Immunosuppressive Regimen	Patient	Max	M/B	Max	M/B
Cyclophosphamide 1000 mg/m ² x 1 Same day as IT	JO-100	1,600	8	6,000	6.7
	BR-101	11,000	110	3,200	32
	JE-120	10,000	100	3,200	32
	LS-121*	3,300	33	2,000	20
	TR-105	25,000	25	15,000	150
	LG-122	12,000	7.5	100	1
	KN-124+	10,000	12.5	10,000	100
	WC-123	30,000	18	8,000	40
	SA-125	20,000	20	50,000	250
Cyclophosphamide 1000 mg/m ² single dose day after IT	RR-31	25,000	8.1	160,000	289
	RY-32	20,000	8	40,000	400
	LR-33	12,500	31.2	60,000	7.5
Azathioprine 3 mg/mk/d x 56 d + Prednisone 0.24 mg/kg/d x 56 d	WR-06*	1,000	1	800	8
	Retreat	1,500	1.8	3,200	32
	MJ-07**	800	8	100	1
	Retreat	11,000	27.5	3,000	30
	Retreat	50,000	50.5	50,000	500
	EP-08*	3,000	8.6	8,000	80
	Retreat	25,000	31.25	40,000	400

*Patient retreated

+Positive skin test before next treatment (treatment not given)

TABLE III (Continued)

Immunosuppressive Regimen	Patient	Max	M/B	Max	M/B
Azathioprine 3 mg/kg/d x 56 d Predisone 0.24 mg/kg/d x 56 d Start 1 week before IT	SC-12	20,000	5	80,000	400
Cyclosporin Daily continuously for 60 days 10-15 mg/kg/day	DM-140*** RS-141*** PS-142** TW-143*** PS-144***	1,000 10,000 3,200 1,200 2,000	1 1.6 1 1.7 1.7	1,000 800 200 200 3,200	1 1 1 1 32
6 MP: 2.5 mg/kg Daily for 21 days	WJ-202* Retreat HA-203* GH 207	5,000 6,400 800 10,000	5 1.6 1 6.2	8,000 6,400 1,600 1,600	1 2 1 8
6 MP: 7.5 mg/kg Daily for 7 days	LK-204 ET-205 MS-206	10,000 3,000 3,200	6.2 1.9 (32)	10,000 800 15,000	12.5 8 (150)

*Patient retreated

+Positive skin test before next treatment (treatment not given)

(): Estimate: no baseline sample

TABLE III (Continued)

Immunosuppressive Regimen	Patient	Max	M/B	Max	M/B
Cyclophosphamide 500 mg/m ² x 3 days	DK-180*	20,000	10	1,200	1.5
+	Retreat	50,000	25	6,400	8
Prednisone 100 mg/day x 3 days	DH-181	12,000	7	500	5

*Patient retreated

+Positive skin test before next treatment (treatment not given)

From the foregoing, it will be appreciated that the use of cyclophosphamide, cyclosporine A, azathioprine and 6-mercaptopurine in concurrent therapy with an immunotoxin substantially reduces the patient's immune response to the immunotoxin components. Thus, multiple immunotoxin treatments are feasible, which increases the effectiveness of immunotoxin therapy and improves the patient's prognosis from the treatment. Moreover, allergic reactions and other harmful aspects of an immune response generated against the immunotoxin are diminished, typically without substantially increasing the toxicity of the overall treatment program.

Although the present invention has been described in some detail by way of example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

20

25

30

35

WHAT IS CLAIMED IS:

1. A method for increasing the effectiveness of immunotoxin based therapy in a human patient undergoing multiple treatment regimens with said immunotoxin; said method comprising concurrently administering with said immunotoxin at least one effective immunosuppressive dose of cyclophosphamide cyclosporine A, azathioprine or 6-mercaptopurine.
2. A method according to claim 1, wherein said cyclophosphamide dose comprises a single intravenous injection of about 1000 mg/m^2 .
3. A method according to claim 1, wherein said cyclophosphamide dose comprises about five injections administered over a period of about eighteen days, each injection about $400 \text{ mg/m}^2/\text{day}$.
4. A method according to claim 1, wherein said cyclophosphamide dose comprises about fourteen daily doses each of about 100 mg/m^2 .
5. A method according to claim 1, wherein said cyclosporine A dose ranges from about 3 to 15 mg/kg/day from about 3 to 60 days.
6. A method according to claim 1, wherein said azathioprene dose ranges from about 1 to 5 mg/kg/day from about 3 to 60 days.
7. A method according to claim 1, wherein said 6-mercaptopurine dose ranges from about 1.5 to 7.5 mg/kg/day from about 1 to 24 days.
8. A method according to claim 1, wherein the immunosuppressive dose is administered with a

therapeutically effective dose of prednisone, dexamethasone and/or mixtures thereof.

9. A method according to claim 1, wherein
5 said patient exhibits an immune response against said monoclonal antibody composition that is reduced by at least about 50 percent from a normal immune response.

10. A method for inhibiting a human immune
10 response against an immunotoxin administered at predetermined intervals for treatment of a tumor, said method comprising concomitantly administering a five-day dose of from about 350 to 600 mg/m²/day of cyclophosphamide; wherein said immunotoxin comprises a cytotoxic agent
15 bound to an antibody specifically reactive with a marker on said tumor.

11. A method according to claim 10, wherein
said cyclophosphamide dose is about 500 mg/m².
20

12. A method for treating a metastatic malignant melanoma in a human patient, said method comprising the steps of:

administering XMMME-001-RTA at a dose of between about 0.1 to 0.4 mg/kg/day over five days; and
25 co-administering cyclophosphamide at a dose of about 500 mg/m²/day at about days 2, 4, 6, 7 and 16; wherein the first step may be repeated at least once without neutralization of the XMMME-001-RTA by antibodies produced by said patient.
30

13. A method for inhibiting a human immune response against an immunotoxin administered in one or more injections over a predetermined treatment protocol,
35 said method comprising co-administering a single immunosuppressive dose of cyclophosphamide.

14. A method according to claim 13, wherein the dose of cyclophosphamide is between about 750-1,250 mg/m².

5

10

15

20

25

30

35